"10.1371_journal.pone.0146256","plos one","2016-01-22T00:00:00Z","Sisi Wang; Hongyong Zhang; Tiffany M Scharadin; Maike Zimmermann; Bin Hu; Amy Wang Pan; Ruth Vinall; Tzu-yin Lin; George Cimino; Patrick Chain; Momchilo Vuyisich; Cheryl Gleasner; Kim Mcmurry; Michael Malfatti; Kenneth Turteltaub; Ralph de Vere White; Chong-xian Pan; Paul T Henderson","Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, California, United States of America; Department of Urology, University of California Davis, Sacramento, California, United States of America; Lawrence Livermore National Laboratory, Livermore, California, United States of America; VA Northern California Health Care System, Mather, California, United States of America; Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America; Accelerated Medical Diagnostics Incorporated, Dublin, California, United States of America","Conceived and designed the experiments: PTH CXP RDW MM PC SW MM BH. Performed the experiments: SW AP BH RV HZ BH TL MV CG KM. Analyzed the data: SW HZ MZ AP TS GC MM CXP PTH MZ. Contributed reagents/materials/analysis tools: KT. Wrote the paper: SW CXP PTH TS MZ PC BH MM.","The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Chong-xian Pan, Paul Henderson and George Cimino are shareholders of Accelerated Medical Diagnostics Incorporated, whose goal is to commercialize the use of drug-DNA adducts as biomarkers of chemotherapy resistance.","2016","01","Sisi Wang","SW",18,TRUE,7,9,9,8,TRUE,TRUE,FALSE,0,NA,FALSE
